secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001437749-26-001140
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports no cardiotoxicity in 90 Annamycin subjects across five trials
-------------------------------------------------------------------------------

- Independent expert review of 90 subjects across five clinical trials found no evidence of cardiotoxicity.
- 65 of 90 subjects received cumulative doses above FDA lifetime max of 550 mg/m2; one exceeded 6,500 mg/m2.
- Data reviewed included serial ECGs, echocardiography with global longitudinal strain, and cardiac troponins.
- Trials covered acute myeloid leukemia and soft tissue sarcoma, both as monotherapy and with cytarabine.
- CEO cites potential for Annamycin to become first non-cardiotoxic anthracycline addressing high unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926001140/0001437749-26-001140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926001140/mbrx20260110c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-001140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer